BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18751922)

  • 1. Glycosphingolipid disorders of the brain.
    Boomkamp SD; Butters TD
    Subcell Biochem; 2008; 49():441-67. PubMed ID: 18751922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
    Butters TD; Dwek RA; Platt FM
    Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal Glycosphingolipid Storage Diseases.
    Breiden B; Sandhoff K
    Annu Rev Biochem; 2019 Jun; 88():461-485. PubMed ID: 31220974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
    Kasperzyk JL; El-Abbadi MM; Hauser EC; D'Azzo A; Platt FM; Seyfried TN
    J Neurochem; 2004 May; 89(3):645-53. PubMed ID: 15086521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system.
    Poenaru L
    Ann Med; 2001 Feb; 33(1):28-36. PubMed ID: 11310936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention.
    Aerts JM; Hollak C; Boot R; Groener A
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):905-14. PubMed ID: 12803924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lysosomes and lysosomal storage diseases].
    Germain DP
    J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of novel NBD-GM1 and NBD-GM2 for the transfer activity of GM2-activator protein by a FRET-based assay system.
    Schwarzmann G; Wendeler M; Sandhoff K
    Glycobiology; 2005 Dec; 15(12):1302-11. PubMed ID: 16079415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal storage disorders in Thailand: the Siriraj experience.
    Wasant P; Wattanaweeradej S; Raksadawan N; Kolodny EH
    Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():54-8. PubMed ID: 8629143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Musculoskeletal complications encountered in the lysosomal storage disorders.
    Pastores GM
    Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):937-47. PubMed ID: 19028373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal storage diseases in adults.
    Rapola J
    Pathol Res Pract; 1994 Sep; 190(8):759-66. PubMed ID: 7831151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis.
    Sandhoff K; Harzer K
    J Neurosci; 2013 Jun; 33(25):10195-208. PubMed ID: 23785136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for lysosomal storage disorders.
    Yew NS; Cheng SH
    Curr Opin Mol Ther; 2001 Aug; 3(4):399-406. PubMed ID: 11525564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developmental analysis of CNS pathology in the lysosomal storage disease alpha-mannosidosis.
    Crawley AC; Walkley SU
    J Neuropathol Exp Neurol; 2007 Aug; 66(8):687-97. PubMed ID: 17882013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
    Sawkar AR; D'Haeze W; Kelly JW
    Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on gene therapy for lysosomal storage diseases that affect hematopoiesis.
    Grabowski GA
    Curr Hematol Rep; 2003 Jul; 2(4):356-62. PubMed ID: 12901334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate reduction therapy.
    Platt FM; Jeyakumar M
    Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.